Datamonitor Healthcare attended the 56th American Society of Hematology (ASH) Annual Meeting and Exposition, which took place between 6 December and 9 December 2014, in San Francisco, California.
Data from Phase I and Phase II trials investigating several therapies based on chimeric antigen receptor T-cells (CAR-Ts) indicated promising efficacy for this class of therapies in the treatment of various B-cell malignancies, including acute lymphocytic leukemia (ALL), chronic lymphocytic leukemia (CLL), and diffuse large B-cell lymphoma (DLBCL).
Monoclonal antibodies (MAbs) continue to advance in pipeline development for multiple myeloma (MM).
Getting a demo tailored to your needs is the best way to see how our solutions will help you gain an advantage.
Request live demo now:
Our team is always happy to hear from you. Please call us at:
Have an immediate and specific information need?
Browse and buy from 1000s of analysis and research reports now: